Literature DB >> 26884996

Effects of Wenyangzhenshuai Granule on ERK1/2 and ERK5 activity in the myocardial tissue in a rabbit model of adriamycin-induced chronic heart failure.

Xinyu Chen1, Huzhi Cai1, Qingyang Chen2, Haibo Xie1, Yuemei Liu1, Qing Lu1, Yanping Tang2.   

Abstract

OBJECTIVE: To elucidate the effects of Wenyangzhenshuai granule on expression of extracellular signal-regulated kinase 1/2 (ERK1/2) and 5 (ERK5) in the myocardial tissue using a rabbit model of adriamycin-induced chronic heart failure.
MATERIALS AND METHODS: Rabbits were divided into heart failure positive control, adriamycin injection, and adriamycin injection with Wenyangzhenshuai treatment (low, medium and high dose) groups. Cardiac function and cardiac hypotrophy were measured in all groups. Besides, myocardial expression of ERK1/2 and ERK5 phosphorylation were evaluated by Western blotting and ERK1/2 and ERK5 mRNA levels by RT-PCR. The cardiac structure and cardiac function were also compared using histology staining and electron microscope.
RESULTS: Adriamycin injection led to cardiac failure reflected by decreased left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), E/A ratio, and increased cardiac hypertrophy, both of which have been improved by Wenyangzhenshuai granule treatment (all P<0.05). Mechanistically, increased P-ERK1/2 and decreased P-ERK5 levels were observed in myocardial tissues of mice treated with Adriamycin for 8 weeks. However, such signaling change could be partially corrected by Wenyangzhenshuai treatment. In addition, no significant difference was detected in the expression of ERK1/2 and ERK5 mRNA levels between adriamycin injection groups and Wenyangzhenshuai treatment groups (P>0.05), indicating an alteration in the activity/phosphorylation levels of these proteins instead of the transcription levels.
CONCLUSION: we found a beneficial effect of Wenyangzhenshuai treatment in partially decelerating the progression of CHF. Such effect was probably through the role of Wenyangzhenchuan in diminishing p-ERK1/2 and raising p-ERK5 level in myocardial tissue.

Entities:  

Keywords:  Chronic heart failure; ERK1/2; ERK5; Wenyangzhenshuai granule; adriamycin; myocardial tissue

Year:  2015        PMID: 26884996      PMCID: PMC4723841     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  14 in total

1.  [Effect of electrical remodeling in hypertrophied myocardium caused by enalapril and its mechanisms].

Authors:  Hou-zhi Yu; Qing Yang; Jue-lin Deng
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2005-06

Review 2.  p38 mitogen-activated protein kinase: a future target for heart failure therapy?

Authors:  Risto Kerkela; Thomas Force
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

Review 3.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

Review 4.  MAPK signalling: ERK5 versus ERK1/2.

Authors:  Satoko Nishimoto; Eisuke Nishida
Journal:  EMBO Rep       Date:  2006-08       Impact factor: 8.807

5.  Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy.

Authors:  Yasuchika Takeishi; Qunhua Huang; Jun-ichi Abe; Wenyi Che; Jiing-Dwan Lee; Hisaaki Kawakatsu; Brian D Hoit; Bradford C Berk; Richard A Walsh
Journal:  Cardiovasc Res       Date:  2002-01       Impact factor: 10.787

6.  Alterations in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure.

Authors:  Rachid Kacimi; Anthony Martin Gerdes
Journal:  Hypertension       Date:  2003-03-17       Impact factor: 10.190

7.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

Authors:  Masaaki Hayashi; Sung-Woo Kim; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; E Dale Abel; Brian Eliceiri; Young Yang; Richard J Ulevitch; Jiing-Dwan Lee
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.

Authors:  R Dale Brown; S Kelly Ambler; Min Li; Timothy M Sullivan; Lauren N Henry; Joseph T Crossno; Carlin S Long; Timothy P Garrington; Kurt R Stenmark
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-02       Impact factor: 4.733

9.  Effect of NOS2 gene deficiency on the development of autoantibody mediated arthritis and subsequent articular cartilage degeneration.

Authors:  Hisayoshi Kato; Keiichiro Nishida; Aki Yoshida; Itsuro Takada; Cherie McCown; Masatsugu Matsuo; Takuro Murakami; Hajime Inoue
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

10.  TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways.

Authors:  Sandra B Haudek; George E Taffet; Michael D Schneider; Douglas L Mann
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more
  3 in total

1.  Effects of Wenyang Zhenshuai Granules on the Expression of Key Mitochondrial Autophagy Proteins in the Doxorubicin-Induced Model of H9c2 Cardiomyocyte Injury.

Authors:  L Q Peng; X X Wu; G Chen; H Z Cai; Y P Tang; Q Y Chen; X Y Chen
Journal:  Bull Exp Biol Med       Date:  2022-07-20       Impact factor: 0.737

2.  Effects of Enalapril on TLR2/NF-κB Signaling Pathway and Inflammatory Factors in Rabbits with Chronic Heart Failure.

Authors:  Yanping Tang; Zelin Xu; Xinyu Chen; Nan Wang; Xu Deng; Liqi Peng; Qingyang Chen; Huzhi Cai
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

Review 3.  ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy.

Authors:  Simona Gallo; Annapia Vitacolonna; Alessandro Bonzano; Paolo Comoglio; Tiziana Crepaldi
Journal:  Int J Mol Sci       Date:  2019-05-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.